SCHEMBL6886569

SCHEMBL6886569

CN1C(=O)/C(=C/c2cc(C(C)(C)C)cc(C(C)(C)C)c2O)SC1=S

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAT1 P18440 1/20 0.53
▸ MEN1 O00255 6/20 0.50
▸ MAPT P10636 6/20 0.50
▸ KMT2A Q03164 6/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ XBP1 P17861 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CGAS Q8N884 1/20 0.48
▸ MAPK1 P28482 2/20 0.47
▸ NOD2 Q9HC29 2/20 0.47
▸ HSP90AA1 P07900 1/20 0.47
▸ OPRM1 P35372 1/20 0.47
▸ OPRD1 P41143 1/20 0.47
▸ CASP3 P42574 1/20 0.47
▸ SENP8 Q96LD8 1/20 0.47
▸ SENP7 Q9BQF6 1/20 0.47
▸ SENP6 Q9GZR1 1/20 0.47
▸ HSD17B3 P37058 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8198993 0.82 NAT1 (0.69) NAT1MEN1KMT2AALDH1A1HSD17B3
SCHEMBL7246592 0.82 NAT1 (0.69) NAT1MEN1KMT2AALDH1A1HSD17B3
SCHEMBL7246589 0.82 NAT1 (0.69) NAT1MEN1KMT2AALDH1A1HSD17B3
SCHEMBL8179956 0.77 PTGS2 (0.69) NAT1MEN1MAPTKMT2AALDH1A1
SCHEMBL8179957 0.77 PTGS2 (0.69) NAT1MEN1MAPTKMT2AALDH1A1
SCHEMBL8710472 0.74 HSD17B3 (0.70) NAT1MEN1MAPTKMT2AALDH1A1
SCHEMBL8710470 0.74 HSD17B3 (0.70) NAT1MEN1MAPTKMT2AALDH1A1
SCHEMBL8492533 0.72 PTGS2 (0.51) MEN1KMT2A
SCHEMBL9429106 0.69 NAT1 (0.51) NAT1MEN1MAPTKMT2AALDH1A1
SCHEMBL9429104 0.69 NAT1 (0.51) NAT1MEN1MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673816-B1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders Esswein, Angelika (DE) 2004-01-06 — — US disclosed
Send feedback